Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Valeant picks up skin care OTCs from J&J; FDA finds ‘supplements’ making anti-meningitis claims; Capsugel supplies Mercola.com; investigation charge slows Omega Protein; Vitacost continues diversifying sales mix more news in brief.

You may also be interested in...



Valeant Keeps Door Open For Consumer Products Acquisitions

The specialty pharmaceutical firm’s consumer products portfolio has grown with the closing of its ophthalmology firm Bausch & Lomb acquisition. Valeant is not ruling out more acquisitions in the consumer products space, CEO J. Michael Pearson says.

Valeant Keeps Door Open For Consumer Products Acquisitions

The specialty pharmaceutical firm’s consumer products portfolio has grown with the closing of its ophthalmology firm Bausch & Lomb acquisition. Valeant is not ruling out more acquisitions in the consumer products space, CEO J. Michael Pearson says.

In Brief

Ramirez appointed FTC chair; budget sequester slows FDA travel, training; ChromaDex divests BluScience brand; Omega Protein buys whey firm; Vitamin Shoppe absorbs integration costs; Vitacost trims net loss in Q4; chemical regulation champion Lautenberg to retire; USANA expands in China.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel